Medical/Pharmaceuticals
Report offers checkup on health of Chinese people in 2020
HANGZHOU, China, Feb. 5, 2021 /PRNewswire/ -- Over 60 percent of respondents held a positive attitude toward the prospects of China's healthcare system and the potential for technologies, a health report found. China Daily app and DX Doctor (DXY), a health information sharing platform, published...
2021-02-05 13:08
3203
TCAI physicians participate in clinical trial for potential life-saving device for patients with heart rhythm disorders
AUSTIN, Texas, Feb. 5, 2021 /PRNewswire/ -- Physicians with the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center are among the first in the world to participate in a clinical trial to evaluate a new esophageal protection device designed to make ablation procedures safer for...
2021-02-05 12:20
2857
Sihuan Pharmaceutical (0460.HK) The sole agent of Letybo 100U China AI Listing Conference was successfully held
HONG KONG, Feb. 5, 2021 /PRNewswire/ -- Exclusively represented by Sihuan Pharmaceutical Holdings Group Ltd. (the "Company" or "Sihuan Pharmaceutical", together with its subsidiaries, collectively referred to as the "Group"; Hong Kong Stock Exchange stock code: 0460), Letybo®100U, a type A botuli...
2021-02-05 11:32
6698
DFI Joins Hands with German ACL to Develop Substantial Business Opportunities in the Smart Medical Market
TAIPEI, Feb. 5, 2021 /PRNewswire/ -- DFI, a leading industrial computer manufacturer, has entered a strategic alliance with ACL, a well-known German medical IT hardware manufacturer, and will combine with DFI's 40 years of rich experience in industrial computers. ACL has been famous in the medica...
2021-02-05 09:00
2782
Global survey presented at the Digital Liver Cancer Summit 2021 reveals heavy toll of COVID-19 first wave on liver cancer care
GENEVA, Feb. 5, 2021 /PRNewswire/ -- The delays of screening programmes, diagnostic imaging and biopsies, cuts in the numbers of physicians available to treat liver cancer patients, cancellations of surgery, and a drop in the number of patients entered on clinical trials, were just some of the is...
2021-02-05 07:00
2999
I-Mab Announces First Patient Dosed in Phase 2 Clinical Trial of TJ107 in Glioblastoma Multiforme in China
SHANGHAI and GAITHERSBURG, Md., Feb. 4, 2021 /PRNewswire/ -- I-Mab (the "Company") (NASDAQ: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the first patient has been dosed in a phase 2 clinic...
2021-02-04 21:00
5473
Covid-19 Drug Duo Achievements: GoldenBiotech's New Drug Antroquinonol (HOCENA) Trial Receives Positive Response from DMC Review and Licenses for 4 Countries
TAIPEI, Feb.4, 2021 /PRNewswire/ -- Golden Biotechnology Corp.(TPEx:4132)("GoldenBiotech"), a leading Taiwanese biopharmaceutical company, announced that it has made two achievements for its Covid-19 new drug candidate Antroquinonol® (HOCENA®): receiving positive response after DMC review in Pha...
2021-02-04 20:30
2105
Covid-19 Drug Duo Achievements: GoldenBiotech's New Drug Antroquinonol (HOCENA) Trial Receives Positive Response from DMC Review and Licenses for 4 Countries
TAIPEI, Feb. 4, 2021 /PRNewswire/ -- Golden Biotechnology Corp.(TPEx:4132)("GoldenBiotech"), a leading Taiwanese biopharmaceutical company, announced that it has made two achievements for its Covid-19 new drug candidate Antroquinonol® (HOCENA®): receiving positive response after DMC review in Ph...
2021-02-04 18:41
2388
Mentice publishes the company's year-end report for the period January-December 2020
STOCKHOLM, Feb. 4, 2021 /PRNewswire/ -- Strong order intake and substantial improvement of the company's order book as well as operating cash flow Fourth quarter (October-December 2020) * Order intake amounted to 73.1 (54.7) MSEK. * Net sales amounted to 45.9 (60.2) MSEK. * Ope...
2021-02-04 16:08
1788
Vemlidy(r) Demonstrates Continued Efficacy and Improved Safety for Asian Patients with Hepatitis B
SINGAPORE, Feb. 4, 2021 /PRNewswire/ -- Gilead Sciences announced today at the 2021 Asian Pacific Association for the Study of the Liver Conference (APASL), findings from two sub-analyses that demonstrated the continued efficacy and improved safety of Vemlidy® (tenofovir alafenamide 25 mg, TAF) ...
2021-02-04 12:00
5127
NCCN Gets Personal About Improving Global Cancer Care for World Cancer Day
Nonprofit alliance behind gold standard oncology guidelines shares stories of personal connections to cancer that inspire many within the organization. Global oncology community looks at the impact from COVID-19 on cancer care over the past year. PLYMOUTH MEETING, Pa., Feb. 4, 2021 /PRNewswire/ ...
2021-02-04 08:05
3959
Edogawa Hospital in Tokyo Installs Japan's First ViewRay MRIdian® Linac
CLEVELAND, Feb. 4, 2021 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that Edogawa Hospital in Tokyo is the first hospital inJapan to treat patients with the MRIdian Linac System. Edogawa Hospital began treating patients in 2018 on the MRIdian cobalt system. The upgrade to MRIdi...
2021-02-04 07:43
8310
FDA Approves TEPMETKO® as the First and Only Once-daily Oral MET Inhibitor for Patients with Metastatic NSCLC with METex14 Skipping Alterations
Not intended for distribution in the USA, Canada or UK - TEPMETKO is approved for both treatment naïve and previously treated MET ex14 positive NSCLC patients - TEPMETKO demonstrated consistent and durable responses in both treatment naïve and previously treatedMETex14 patients in the VISION stud...
2021-02-04 02:57
1917
Eucure Biopharma Announces Encouraging Antitumor Activity of Its anti-CD40 Antibody in PD-1 Refractory Ocular Melanoma when Combined with Junshi Biosciences' Toripalimab
BOSTON and BEIJING, Feb. 3, 2021 /PRNewswire/ -- Eucure Biopharma, a biopharmaceutical company dedicated to developing immuno-oncology antibody drugs, announced that its investigational anti-CD40 antibody drug (YH003), when combined with Junshi Biosciences' anti-PD-1 antibody Toripalimab (TUOYI®)...
2021-02-03 23:45
5968
More Patients Set to Benefit as Kanghong Pharmaceutical Targets New Indications with Conbercept
CHENGDU, China, Feb. 3, 2021 /PRNewswire/ -- Chengdu Kanghong Pharmaceutical Group ("Kanghong", SHE: 002773), has received Special Protocol Assessments from the Food and Drug Administration for three new indications for its biologic drug conbercept. The drug is an anti-VEGF fusion protein, approv...
2021-02-03 22:00
4779
Longevity Acquisition Corporation Announces 4D pharma Update on Oncology Program
NEW YORK, Feb. 3, 2021 /PRNewswire/ -- Longevity Acquisition Corporation (NASDAQ: LOAC) (the "Company"), a publicly-traded special purpose acquisition company, announced today that onFebruary 3, 2021, 4D pharma plc (AIM: DDDD) ("4D pharma"), a pharmaceutical company leading the development of Liv...
2021-02-03 22:00
7451
Guardant360 CDx submitted for regulatory approval in Japan
TOKYO, Feb. 3, 2021 /PRNewswire/ -- Guardant Health Japan, an affiliate of Guardant Health Asia,Middle East & Africa (AMEA) has announced that it has submitted its application to the Ministry of Health, Labour and Welfare (MHLW) for regulatory approval of Guardant360 CDx, a liquid biopsy test for...
2021-02-03 18:41
3589
Innovent and Lilly Jointly Announce the Approval of TYVYT® (sintilimab injection) by China NMPA in Combination with Pemetrexed and Platinum Chemotherapy as First-Line Therapy for Nonsquamous Non-Small Cell Lung Cancer
SAN FRANCISCO and SUZHOU, China, Feb. 3, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major disease...
2021-02-03 12:30
10222
Ping An Healthcare and Technology Company Limited posts revenue of RMB 6,866 million in 2020
Launches comprehensive strategic upgrade Revenue from online medical services, its core business, grows 82.4% year-on-year HONG KONG, Feb. 3, 2021 /PRNewswire/ -- Ping An Healthcare and Technology Company Limited ("Ping An Good Doctor"; Stock Code: 01833.HK), a leading internet healthcare se...
2021-02-03 01:03
8885
Elekta's MOSAIQ and Versa HD earn top honors in 2021 Best in KLAS: Software and Services Report
ATLANTA, Feb. 3, 2021 /PRNewswire/ -- Elekta (EKTA-B.ST) today announced that itsMOSAIQ® Oncology Information System (OIS) and Versa HD™ linear accelerator have been named "Best in KLAS" in the 2021 Best in KLAS: Software and Services Report. MOSAIQ was ranked first in the Oncology (Radiation) ca...
2021-02-03 00:30
4001
Week's Top Stories
Most Reposted
Edufrienz 99: One of Asia's First Digital Platform Advancing Character Education for Future-Ready, Compassionate Children
[Picked up by 315 media titles]
2026-01-23 11:03
UOB prices AUD2 billion in five-year senior unsecured notes
[Picked up by 305 media titles]
2026-01-23 09:00AVPN's AI Opportunity Fund Expands Regional Efforts to Build AI Skilling Infrastructure for a Future-Ready Workforce Across Asia-Pacific
[Picked up by 302 media titles]
2026-01-21 12:39Government of Telangana and Blaize Sign MoU at Davos to Launch Telangana AI Innovation Hub and Advance Applied AI Initiatives
[Picked up by 297 media titles]
2026-01-22 15:16
Klook's study of 374,000 reviews finds that lesser-known cities create deeper emotional connection with travelers
[Picked up by 280 media titles]
2026-01-20 15:40
Most Read
Building the Run: Xtep Charts a New Community Ecosystem in Southeast Asia
2026-01-20 17:49
6000
